Difference between revisions of "Migraine"
| (One intermediate revision by the same user not shown) | |||
| Line 28: | Line 28: | ||
Requires clonidine as prophylaxis (preventative medication) | Requires clonidine as prophylaxis (preventative medication) | ||
| − | Monoclonal antibodies are used for migraine prophylaxis. In the UK, erenumab (aimovig), fremanezumab (ajovy), galcanezumab (emgality) are the monoclonal antibodies licensed for use. | + | Monoclonal antibodies are used for migraine prophylaxis. In the UK, erenumab (aimovig), fremanezumab (ajovy), galcanezumab (emgality) are the monoclonal antibodies licensed for use. Past or current use of monoclonal antibodies is a permanent exclusion. |
====Acceptable==== | ====Acceptable==== | ||
| Line 40: | Line 40: | ||
==Version== | ==Version== | ||
| − | Version 1, Edition | + | Version 1, Edition 3 |
====Date of Last Update==== | ====Date of Last Update==== | ||
| − | + | 23 July 2025 | |
Latest revision as of 16:21, 24 July 2025
Contents
Acceptability at Recruitment
QUALIFIED
Acceptability at CT / Work-Up
QUALIFIED
Individual at Risk
Donor
Explanation of Condition
Intermittent headaches associated with nausea and visual phenomena (aura), such as zig-zag lines or halos.
See also Migraine
Guidance
Guidance at registration
Unacceptable
Donors taking the following medications should not be accepted onto the register: Clonidine, Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality).
Otherwise, acceptable.
Guidance at VT
Unacceptable
Severe, having more than two attacks per month
Requires clonidine as prophylaxis (preventative medication)
Monoclonal antibodies are used for migraine prophylaxis. In the UK, erenumab (aimovig), fremanezumab (ajovy), galcanezumab (emgality) are the monoclonal antibodies licensed for use. Past or current use of monoclonal antibodies is a permanent exclusion.
Acceptable
Uses pizotifen (Sanomigran) or beta-blocker as prophylaxis
Discuss with medical officer if unclear.
Pseudonyms or Related Conditions
Version
Version 1, Edition 3
Date of Last Update
23 July 2025
